The safety of anidulafungin.
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.
Vazquez
José A
JA
Senior Staff, Henry Ford Hospital, Division of Infectious Diseases, 2799 West Grand Boulevard, CFP-202, Detroit, MI 48202, USA. jvazque1@hfhs.org
D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects* / Q000097:blood; D054714:Echinocandins; D006801:Humans; D010456:Peptides, Cyclic / Q000009:adverse effects* / Q000097:blood
D000935:Antifungal Agents; D054714:Echinocandins; D010456:Peptides, Cyclic; D000077612:Anidulafungin